AI Engines For more Details: Perplexity Kagi Labs You
Antifungal Activity: Oxiconazole nitrate works by inhibiting the growth of fungi by interfering with their cell membrane synthesis, leading to the disruption of their cellular structure and function. This action helps to eliminate fungal infections and relieve associated symptoms such as itching, redness, and inflammation.
Indications: Oxiconazole nitrate is indicated for the topical treatment of superficial fungal infections of the skin caused by dermatophytes, yeasts, and other susceptible fungi. It is commonly prescribed for conditions such as athlete's foot, jock itch, and ringworm.
Topical Application: Oxiconazole nitrate is typically applied to the affected area of the skin as a cream or lotion. It should be applied thinly and evenly, covering the affected skin and a small surrounding area, according to the healthcare provider's instructions.
Efficacy: Clinical studies have demonstrated the efficacy of oxiconazole nitrate in the treatment of fungal skin infections. Improvement in symptoms such as itching, redness, and scaling is usually observed within a few days of starting treatment, although complete resolution of the infection may take several weeks.
Side Effects: Common side effects associated with the use of oxiconazole nitrate include mild burning, stinging, itching, or irritation at the application site. These side effects are usually temporary and resolve on their own. However, if they persist or worsen, patients should discontinue use and consult their healthcare provider.
Allergic Reactions: Although rare, allergic reactions to oxiconazole nitrate may occur. Signs of an allergic reaction include rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, or trouble breathing. Patients should seek immediate medical attention if they experience any of these symptoms.
Precautions: Oxiconazole nitrate should be used with caution in individuals with a known allergy to azole antifungal medications or any other components of the formulation. It should not be ingested or applied to the eyes, mouth, or mucous membranes.
Drug Interactions: There are no significant drug interactions reported with topical oxiconazole nitrate. However, patients should inform their healthcare provider about all medications, including over-the-counter drugs and herbal supplements, to avoid potential interactions.
Pregnancy and Lactation: The safety of oxiconazole nitrate during pregnancy and lactation has not been well established. Pregnant or breastfeeding women should consult their healthcare provider before using this medication.
Children and Elderly: Oxiconazole nitrate is generally considered safe for use in children and elderly individuals when used as directed. However, dosage adjustments or special precautions may be necessary in these populations, and healthcare provider guidance should be followed.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 4.2 | 0.9 | 3.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 1.8 | 0.89 |
| Allergies | 6.4 | 2.7 | 1.37 |
| Allergy to milk products | 1.5 | 1.6 | -0.07 |
| Alopecia (Hair Loss) | 1.7 | 1.7 | |
| Alzheimer's disease | 5.6 | 7.6 | -0.36 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.2 | 0.4 | 7 |
| Ankylosing spondylitis | 4.2 | 1.5 | 1.8 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.6 | 0.3 | 4.33 |
| Asthma | 5.2 | 1.5 | 2.47 |
| Atherosclerosis | 1.9 | 2.4 | -0.26 |
| Atrial fibrillation | 3.8 | 3.1 | 0.23 |
| Autism | 10.2 | 9.1 | 0.12 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.6 | 1.6 | |
| Bipolar Disorder | 2.4 | 1.4 | 0.71 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.3 | 2.4 | -7 |
| Carcinoma | 4.1 | 2.6 | 0.58 |
| Celiac Disease | 2.8 | 3.3 | -0.18 |
| Cerebral Palsy | 1.1 | 1.3 | -0.18 |
| Chronic Fatigue Syndrome | 5.6 | 7.2 | -0.29 |
| Chronic Kidney Disease | 4.6 | 2.9 | 0.59 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 1.4 | 0.36 |
| Chronic Urticaria (Hives) | 1.2 | 1.2 | 0 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 7.7 | 2.3 | 2.35 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 2.5 | 2.7 | -0.08 |
| COVID-19 | 9.8 | 12.9 | -0.32 |
| Crohn's Disease | 8.3 | 5.5 | 0.51 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.7 | 1.4 | -1 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 2.6 | 1.4 | 0.86 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 11.3 | 9.4 | 0.2 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 2.1 | -0.24 |
| Endometriosis | 3 | 1.9 | 0.58 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 3.2 | 1.7 | 0.88 |
| erectile dysfunction | 2.3 | 0.3 | 6.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 6.2 | 4.6 | 0.35 |
| gallstone disease (gsd) | 3.6 | 0.8 | 3.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 1.2 | 0 |
| Generalized anxiety disorder | 2.6 | 2.3 | 0.13 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.3 | 0.8 | 0.63 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.9 | 1.5 | -0.67 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 3.3 | 1.8 | 0.83 |
| Heart Failure | 4.3 | 1.9 | 1.26 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 1.5 | 0.6 | 1.5 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 1.3 | 1.1 | 0.18 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.7 | 5.6 | -0.19 |
| Hypothyroidism | 1 | -1 | |
| Hypoxia | 3.1 | 0.9 | 2.44 |
| IgA nephropathy (IgAN) | 1.6 | 4.7 | -1.94 |
| Inflammatory Bowel Disease | 9.5 | 9.2 | 0.03 |
| Insomnia | 2.2 | 2.1 | 0.05 |
| Intelligence | 1.5 | 0.6 | 1.5 |
| Intracranial aneurysms | 1.2 | 0.9 | 0.33 |
| Irritable Bowel Syndrome | 6.7 | 5.1 | 0.31 |
| ischemic stroke | 2.2 | 1.7 | 0.29 |
| Liver Cirrhosis | 7 | 3.2 | 1.19 |
| Long COVID | 7.4 | 7.8 | -0.05 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.2 | 1 | 0.2 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.5 | -0.25 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.4 | 0.5 | 1.8 |
| Metabolic Syndrome | 7.8 | 7.2 | 0.08 |
| Mood Disorders | 10.5 | 7.9 | 0.33 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 7.4 | 7.1 | 0.04 |
| Multiple system atrophy (MSA) | 1.2 | 0.7 | 0.71 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.9 | -8.67 |
| Neuropathy (all types) | 0.7 | 2.6 | -2.71 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.8 | 4.1 | 0.41 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 10.6 | 7.5 | 0.41 |
| obsessive-compulsive disorder | 6.3 | 4.2 | 0.5 |
| Osteoarthritis | 3.3 | 1.2 | 1.75 |
| Osteoporosis | 2.2 | 1.3 | 0.69 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 8.4 | 7.7 | 0.09 |
| Polycystic ovary syndrome | 7.7 | 3.2 | 1.41 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.9 | 1.4 | -0.56 |
| Primary sclerosing cholangitis | 1.8 | 3.3 | -0.83 |
| Psoriasis | 3.2 | 3.4 | -0.06 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.3 | 4.1 | 1.02 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 5.3 | 2.8 | 0.89 |
| scoliosis | 0.4 | 1.2 | -2 |
| Sjögren syndrome | 2.3 | 2.7 | -0.17 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.3 | 1.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0.4 | 2 |
| Stress / posttraumatic stress disorder | 2.5 | 2.7 | -0.08 |
| Systemic Lupus Erythematosus | 4.3 | 2.4 | 0.79 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 4.3 | 3.6 | 0.19 |
| Type 2 Diabetes | 8.9 | 7 | 0.27 |
| Ulcerative colitis | 5.6 | 7.8 | -0.39 |
| Unhealthy Ageing | 5.6 | 2.4 | 1.33 |
| Vitiligo | 2.5 | 1.5 | 0.67 |
